Compounds > 4-nitro-3-dimethylaminopropiophenone
Page last updated: 2024-11-08

4-nitro-3-dimethylaminopropiophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitro-3-dimethylaminopropiophenone: NO(2) group responsible for required electron affinity; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID192756
SCHEMBL ID1727397
MeSH IDM0075813

Synonyms (16)

Synonym
5424-48-6
ndpp
3-(dimethylamino)-1-(4-nitrophenyl)-1-propanone
STK033843
3-(dimethylamino)-1-(4-nitrophenyl)propan-1-one
4-nitro-3-dimethylaminopropiophenone
p-nitro-3-dimethylaminopropiophenone hydrochloride
beta-n,n-dimethyl-4-itropropiophenone
4-nitro-3-dimethylaminopropiophenone hydrochloride
2138-40-1
beta-n,n-dimethyl-p-nitropropiophenone
1-propanone,3-(dimethylamino)-1-(4-nitrophenyl)-, hydrobromide (1:1)
SCHEMBL1727397
SJPJHLBDGCNLAL-UHFFFAOYSA-N
3-dimethylamino-1-(4-nitrophenyl)propan-1-one
DTXSID60175642
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (12.50%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.3620C-nitro compound;
imidazoles		antitubercular agent
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		05.9551
Prediabetes
[description not available]		05.221
Weight Reduction
[description not available]		05.221
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		05.9551
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).		05.221
Weight Loss
Decrease in existing BODY WEIGHT.		05.221
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.610
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		02.610
Diabetes Mellitus, Gestational
[description not available]		02.610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.610
Diabetes, Gestational
Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.		02.610
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		01.9510
Metastase
[description not available]		01.9510
Experimental Mammary Neoplasms
[description not available]		01.9510
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9510
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		01.9510